Neoadjuvant induction dose-dense MVAC for muscle invasive bladder cancer: efficacy and safety compared with classic MVAC and gemcitabine/cisplatin
Purpose To investigate the efficacy and safety of neoadjuvant induction dose-dense MVAC (dd-MVAC) for muscle invasive bladder cancer (MIBC). Results of the 2-week-per-cycle regimen were compared with classic MVAC (4 weeks per cycle) and gemcitabine/cisplatin (GC, 3 weeks per cycle). Methods We inclu...
Gespeichert in:
| Veröffentlicht in: | World journal of urology 2016-02, Vol.34 (2), p.157-162 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 162 |
|---|---|
| container_issue | 2 |
| container_start_page | 157 |
| container_title | World journal of urology |
| container_volume | 34 |
| creator | van de Putte, Elisabeth E. Fransen Mertens, Laura S. Meijer, Richard P. van der Heijden, Michiel S. Bex, Axel van der Poel, Henk G. Kerst, J. Martijn Bergman, Andries M. Horenblas, Simon van Rhijn, Bas W. G. |
| description | Purpose
To investigate the efficacy and safety of neoadjuvant induction dose-dense MVAC (dd-MVAC) for muscle invasive bladder cancer (MIBC). Results of the 2-week-per-cycle regimen were compared with classic MVAC (4 weeks per cycle) and gemcitabine/cisplatin (GC, 3 weeks per cycle).
Methods
We included 166 patients with non-organ-confined MIBC, who received neoadjuvant induction dd-MVAC (80), classic MVAC (35), or GC (51) between 1990 and 2014. Complete pathological response (pCR) was defined as no evidence of residual tumor in cystectomy and lymphadenectomy specimens (ypT0N0). pCR and toxicity rates were compared among regimens.
Results
pCR was found in 29 % of dd-MVAC-treated patients, which was not significantly different from classic MVAC (20 %,
p
= 0.366) and GC (32 %,
p
= 0.845). Grade 3–4 toxicity rates related to dd-MVAC and GC (44 %) were similar (
p
= 0.202), whereas the toxicity rate for classic MVAC (55 %) was significantly higher than for dd-MVAC (32 %) uncorrected (
p
= 0.026) and corrected for patient and tumor characteristics (OR 2.84,
p
= 0.037).
Conclusions
Neoadjuvant induction dd-MVAC resulted in pathological response rates similar to classic MVAC and GC treatment in patients with non-organ-confined MIBC. The shorter cycle duration compared with classic MVAC and GC and the significantly lower toxicity rate compared with classic MVAC indicate that dd-MVAC should be the preferred option for neoadjuvant induction treatment. |
| doi_str_mv | 10.1007/s00345-015-1636-y |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_1760724216</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3934996711</sourcerecordid><originalsourceid>FETCH-LOGICAL-c442t-a6c5aaae4ac6596efc0eb6bb00774cbab4d5a891e74c641321602599a7a736eb3</originalsourceid><addsrcrecordid>eNp1kUFP3DAQhS3UChbaH9BLZalng504zqY3tGoLEpQLcLXG9oR6lThbO9kqf6O_uF4FUC-cRqP53hvpPUI-CX4uOK8vEuelrBgXFROqVGw-Iishy5Kt60K9IyteF5LJZl2ekNOUtpyLWvHqmJwUSqyl4GpF_v7EAdx22kMYqQ9usqMfAnVDQuYwJKS3j5cb2g6R9lOyHWZoD8nvkZoOnMNILQSL8SvFtvUW7EwhOJqgxXGmduh3ENHRP378RW0HKXm7WB6oJ-ytH8H4gBfWp10How8fyPsWuoQfn-cZefj-7X5zxW7uflxvLm-YlbIYGShbAQBKsKpqFLaWo1HG5GBqaQ0Y6SpYNwLzpqQoC6F4UTUN1FCXCk15Rr4svrs4_J4wjXo7TDHkl_qQU84uSzIlFsrGIaWIrd5F30OcteD60IJeWtC5BX1oQc9Z8_nZeTI9ulfFS-wZKBYg5VN4wvjf6zdd_wHF-pUd</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1760724216</pqid></control><display><type>article</type><title>Neoadjuvant induction dose-dense MVAC for muscle invasive bladder cancer: efficacy and safety compared with classic MVAC and gemcitabine/cisplatin</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><creator>van de Putte, Elisabeth E. Fransen ; Mertens, Laura S. ; Meijer, Richard P. ; van der Heijden, Michiel S. ; Bex, Axel ; van der Poel, Henk G. ; Kerst, J. Martijn ; Bergman, Andries M. ; Horenblas, Simon ; van Rhijn, Bas W. G.</creator><creatorcontrib>van de Putte, Elisabeth E. Fransen ; Mertens, Laura S. ; Meijer, Richard P. ; van der Heijden, Michiel S. ; Bex, Axel ; van der Poel, Henk G. ; Kerst, J. Martijn ; Bergman, Andries M. ; Horenblas, Simon ; van Rhijn, Bas W. G.</creatorcontrib><description>Purpose
To investigate the efficacy and safety of neoadjuvant induction dose-dense MVAC (dd-MVAC) for muscle invasive bladder cancer (MIBC). Results of the 2-week-per-cycle regimen were compared with classic MVAC (4 weeks per cycle) and gemcitabine/cisplatin (GC, 3 weeks per cycle).
Methods
We included 166 patients with non-organ-confined MIBC, who received neoadjuvant induction dd-MVAC (80), classic MVAC (35), or GC (51) between 1990 and 2014. Complete pathological response (pCR) was defined as no evidence of residual tumor in cystectomy and lymphadenectomy specimens (ypT0N0). pCR and toxicity rates were compared among regimens.
Results
pCR was found in 29 % of dd-MVAC-treated patients, which was not significantly different from classic MVAC (20 %,
p
= 0.366) and GC (32 %,
p
= 0.845). Grade 3–4 toxicity rates related to dd-MVAC and GC (44 %) were similar (
p
= 0.202), whereas the toxicity rate for classic MVAC (55 %) was significantly higher than for dd-MVAC (32 %) uncorrected (
p
= 0.026) and corrected for patient and tumor characteristics (OR 2.84,
p
= 0.037).
Conclusions
Neoadjuvant induction dd-MVAC resulted in pathological response rates similar to classic MVAC and GC treatment in patients with non-organ-confined MIBC. The shorter cycle duration compared with classic MVAC and GC and the significantly lower toxicity rate compared with classic MVAC indicate that dd-MVAC should be the preferred option for neoadjuvant induction treatment.</description><identifier>ISSN: 0724-4983</identifier><identifier>EISSN: 1433-8726</identifier><identifier>DOI: 10.1007/s00345-015-1636-y</identifier><identifier>PMID: 26184106</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Bladder cancer ; Carcinoma, Transitional Cell - drug therapy ; Carcinoma, Transitional Cell - pathology ; Cisplatin - administration & dosage ; Cisplatin - therapeutic use ; Deoxycytidine - administration & dosage ; Deoxycytidine - analogs & derivatives ; Dose-Response Relationship, Drug ; Doxorubicin - therapeutic use ; Female ; Follow-Up Studies ; Humans ; Male ; Medicine ; Medicine & Public Health ; Methotrexate - therapeutic use ; Middle Aged ; Neoplasm Invasiveness ; Nephrology ; Oncology ; Original Article ; Retrospective Studies ; Time Factors ; Treatment Outcome ; Urinary Bladder Neoplasms - drug therapy ; Urinary Bladder Neoplasms - pathology ; Urology ; Vinblastine - therapeutic use</subject><ispartof>World journal of urology, 2016-02, Vol.34 (2), p.157-162</ispartof><rights>Springer-Verlag Berlin Heidelberg 2015</rights><rights>Springer-Verlag Berlin Heidelberg 2016</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c442t-a6c5aaae4ac6596efc0eb6bb00774cbab4d5a891e74c641321602599a7a736eb3</citedby><cites>FETCH-LOGICAL-c442t-a6c5aaae4ac6596efc0eb6bb00774cbab4d5a891e74c641321602599a7a736eb3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00345-015-1636-y$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00345-015-1636-y$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27903,27904,41467,42536,51297</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26184106$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>van de Putte, Elisabeth E. Fransen</creatorcontrib><creatorcontrib>Mertens, Laura S.</creatorcontrib><creatorcontrib>Meijer, Richard P.</creatorcontrib><creatorcontrib>van der Heijden, Michiel S.</creatorcontrib><creatorcontrib>Bex, Axel</creatorcontrib><creatorcontrib>van der Poel, Henk G.</creatorcontrib><creatorcontrib>Kerst, J. Martijn</creatorcontrib><creatorcontrib>Bergman, Andries M.</creatorcontrib><creatorcontrib>Horenblas, Simon</creatorcontrib><creatorcontrib>van Rhijn, Bas W. G.</creatorcontrib><title>Neoadjuvant induction dose-dense MVAC for muscle invasive bladder cancer: efficacy and safety compared with classic MVAC and gemcitabine/cisplatin</title><title>World journal of urology</title><addtitle>World J Urol</addtitle><addtitle>World J Urol</addtitle><description>Purpose
To investigate the efficacy and safety of neoadjuvant induction dose-dense MVAC (dd-MVAC) for muscle invasive bladder cancer (MIBC). Results of the 2-week-per-cycle regimen were compared with classic MVAC (4 weeks per cycle) and gemcitabine/cisplatin (GC, 3 weeks per cycle).
Methods
We included 166 patients with non-organ-confined MIBC, who received neoadjuvant induction dd-MVAC (80), classic MVAC (35), or GC (51) between 1990 and 2014. Complete pathological response (pCR) was defined as no evidence of residual tumor in cystectomy and lymphadenectomy specimens (ypT0N0). pCR and toxicity rates were compared among regimens.
Results
pCR was found in 29 % of dd-MVAC-treated patients, which was not significantly different from classic MVAC (20 %,
p
= 0.366) and GC (32 %,
p
= 0.845). Grade 3–4 toxicity rates related to dd-MVAC and GC (44 %) were similar (
p
= 0.202), whereas the toxicity rate for classic MVAC (55 %) was significantly higher than for dd-MVAC (32 %) uncorrected (
p
= 0.026) and corrected for patient and tumor characteristics (OR 2.84,
p
= 0.037).
Conclusions
Neoadjuvant induction dd-MVAC resulted in pathological response rates similar to classic MVAC and GC treatment in patients with non-organ-confined MIBC. The shorter cycle duration compared with classic MVAC and GC and the significantly lower toxicity rate compared with classic MVAC indicate that dd-MVAC should be the preferred option for neoadjuvant induction treatment.</description><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Bladder cancer</subject><subject>Carcinoma, Transitional Cell - drug therapy</subject><subject>Carcinoma, Transitional Cell - pathology</subject><subject>Cisplatin - administration & dosage</subject><subject>Cisplatin - therapeutic use</subject><subject>Deoxycytidine - administration & dosage</subject><subject>Deoxycytidine - analogs & derivatives</subject><subject>Dose-Response Relationship, Drug</subject><subject>Doxorubicin - therapeutic use</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Humans</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Methotrexate - therapeutic use</subject><subject>Middle Aged</subject><subject>Neoplasm Invasiveness</subject><subject>Nephrology</subject><subject>Oncology</subject><subject>Original Article</subject><subject>Retrospective Studies</subject><subject>Time Factors</subject><subject>Treatment Outcome</subject><subject>Urinary Bladder Neoplasms - drug therapy</subject><subject>Urinary Bladder Neoplasms - pathology</subject><subject>Urology</subject><subject>Vinblastine - therapeutic use</subject><issn>0724-4983</issn><issn>1433-8726</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp1kUFP3DAQhS3UChbaH9BLZalng504zqY3tGoLEpQLcLXG9oR6lThbO9kqf6O_uF4FUC-cRqP53hvpPUI-CX4uOK8vEuelrBgXFROqVGw-Iishy5Kt60K9IyteF5LJZl2ekNOUtpyLWvHqmJwUSqyl4GpF_v7EAdx22kMYqQ9usqMfAnVDQuYwJKS3j5cb2g6R9lOyHWZoD8nvkZoOnMNILQSL8SvFtvUW7EwhOJqgxXGmduh3ENHRP378RW0HKXm7WB6oJ-ytH8H4gBfWp10How8fyPsWuoQfn-cZefj-7X5zxW7uflxvLm-YlbIYGShbAQBKsKpqFLaWo1HG5GBqaQ0Y6SpYNwLzpqQoC6F4UTUN1FCXCk15Rr4svrs4_J4wjXo7TDHkl_qQU84uSzIlFsrGIaWIrd5F30OcteD60IJeWtC5BX1oQc9Z8_nZeTI9ulfFS-wZKBYg5VN4wvjf6zdd_wHF-pUd</recordid><startdate>20160201</startdate><enddate>20160201</enddate><creator>van de Putte, Elisabeth E. Fransen</creator><creator>Mertens, Laura S.</creator><creator>Meijer, Richard P.</creator><creator>van der Heijden, Michiel S.</creator><creator>Bex, Axel</creator><creator>van der Poel, Henk G.</creator><creator>Kerst, J. Martijn</creator><creator>Bergman, Andries M.</creator><creator>Horenblas, Simon</creator><creator>van Rhijn, Bas W. G.</creator><general>Springer Berlin Heidelberg</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>20160201</creationdate><title>Neoadjuvant induction dose-dense MVAC for muscle invasive bladder cancer: efficacy and safety compared with classic MVAC and gemcitabine/cisplatin</title><author>van de Putte, Elisabeth E. Fransen ; Mertens, Laura S. ; Meijer, Richard P. ; van der Heijden, Michiel S. ; Bex, Axel ; van der Poel, Henk G. ; Kerst, J. Martijn ; Bergman, Andries M. ; Horenblas, Simon ; van Rhijn, Bas W. G.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c442t-a6c5aaae4ac6596efc0eb6bb00774cbab4d5a891e74c641321602599a7a736eb3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Bladder cancer</topic><topic>Carcinoma, Transitional Cell - drug therapy</topic><topic>Carcinoma, Transitional Cell - pathology</topic><topic>Cisplatin - administration & dosage</topic><topic>Cisplatin - therapeutic use</topic><topic>Deoxycytidine - administration & dosage</topic><topic>Deoxycytidine - analogs & derivatives</topic><topic>Dose-Response Relationship, Drug</topic><topic>Doxorubicin - therapeutic use</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Humans</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Methotrexate - therapeutic use</topic><topic>Middle Aged</topic><topic>Neoplasm Invasiveness</topic><topic>Nephrology</topic><topic>Oncology</topic><topic>Original Article</topic><topic>Retrospective Studies</topic><topic>Time Factors</topic><topic>Treatment Outcome</topic><topic>Urinary Bladder Neoplasms - drug therapy</topic><topic>Urinary Bladder Neoplasms - pathology</topic><topic>Urology</topic><topic>Vinblastine - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>van de Putte, Elisabeth E. Fransen</creatorcontrib><creatorcontrib>Mertens, Laura S.</creatorcontrib><creatorcontrib>Meijer, Richard P.</creatorcontrib><creatorcontrib>van der Heijden, Michiel S.</creatorcontrib><creatorcontrib>Bex, Axel</creatorcontrib><creatorcontrib>van der Poel, Henk G.</creatorcontrib><creatorcontrib>Kerst, J. Martijn</creatorcontrib><creatorcontrib>Bergman, Andries M.</creatorcontrib><creatorcontrib>Horenblas, Simon</creatorcontrib><creatorcontrib>van Rhijn, Bas W. G.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>World journal of urology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>van de Putte, Elisabeth E. Fransen</au><au>Mertens, Laura S.</au><au>Meijer, Richard P.</au><au>van der Heijden, Michiel S.</au><au>Bex, Axel</au><au>van der Poel, Henk G.</au><au>Kerst, J. Martijn</au><au>Bergman, Andries M.</au><au>Horenblas, Simon</au><au>van Rhijn, Bas W. G.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Neoadjuvant induction dose-dense MVAC for muscle invasive bladder cancer: efficacy and safety compared with classic MVAC and gemcitabine/cisplatin</atitle><jtitle>World journal of urology</jtitle><stitle>World J Urol</stitle><addtitle>World J Urol</addtitle><date>2016-02-01</date><risdate>2016</risdate><volume>34</volume><issue>2</issue><spage>157</spage><epage>162</epage><pages>157-162</pages><issn>0724-4983</issn><eissn>1433-8726</eissn><abstract>Purpose
To investigate the efficacy and safety of neoadjuvant induction dose-dense MVAC (dd-MVAC) for muscle invasive bladder cancer (MIBC). Results of the 2-week-per-cycle regimen were compared with classic MVAC (4 weeks per cycle) and gemcitabine/cisplatin (GC, 3 weeks per cycle).
Methods
We included 166 patients with non-organ-confined MIBC, who received neoadjuvant induction dd-MVAC (80), classic MVAC (35), or GC (51) between 1990 and 2014. Complete pathological response (pCR) was defined as no evidence of residual tumor in cystectomy and lymphadenectomy specimens (ypT0N0). pCR and toxicity rates were compared among regimens.
Results
pCR was found in 29 % of dd-MVAC-treated patients, which was not significantly different from classic MVAC (20 %,
p
= 0.366) and GC (32 %,
p
= 0.845). Grade 3–4 toxicity rates related to dd-MVAC and GC (44 %) were similar (
p
= 0.202), whereas the toxicity rate for classic MVAC (55 %) was significantly higher than for dd-MVAC (32 %) uncorrected (
p
= 0.026) and corrected for patient and tumor characteristics (OR 2.84,
p
= 0.037).
Conclusions
Neoadjuvant induction dd-MVAC resulted in pathological response rates similar to classic MVAC and GC treatment in patients with non-organ-confined MIBC. The shorter cycle duration compared with classic MVAC and GC and the significantly lower toxicity rate compared with classic MVAC indicate that dd-MVAC should be the preferred option for neoadjuvant induction treatment.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>26184106</pmid><doi>10.1007/s00345-015-1636-y</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0724-4983 |
| ispartof | World journal of urology, 2016-02, Vol.34 (2), p.157-162 |
| issn | 0724-4983 1433-8726 |
| language | eng |
| recordid | cdi_proquest_journals_1760724216 |
| source | MEDLINE; Springer Nature - Complete Springer Journals |
| subjects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use Bladder cancer Carcinoma, Transitional Cell - drug therapy Carcinoma, Transitional Cell - pathology Cisplatin - administration & dosage Cisplatin - therapeutic use Deoxycytidine - administration & dosage Deoxycytidine - analogs & derivatives Dose-Response Relationship, Drug Doxorubicin - therapeutic use Female Follow-Up Studies Humans Male Medicine Medicine & Public Health Methotrexate - therapeutic use Middle Aged Neoplasm Invasiveness Nephrology Oncology Original Article Retrospective Studies Time Factors Treatment Outcome Urinary Bladder Neoplasms - drug therapy Urinary Bladder Neoplasms - pathology Urology Vinblastine - therapeutic use |
| title | Neoadjuvant induction dose-dense MVAC for muscle invasive bladder cancer: efficacy and safety compared with classic MVAC and gemcitabine/cisplatin |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-24T13%3A02%3A18IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Neoadjuvant%20induction%20dose-dense%20MVAC%20for%20muscle%20invasive%20bladder%20cancer:%20efficacy%20and%20safety%20compared%20with%20classic%20MVAC%20and%20gemcitabine/cisplatin&rft.jtitle=World%20journal%20of%20urology&rft.au=van%20de%20Putte,%20Elisabeth%20E.%20Fransen&rft.date=2016-02-01&rft.volume=34&rft.issue=2&rft.spage=157&rft.epage=162&rft.pages=157-162&rft.issn=0724-4983&rft.eissn=1433-8726&rft_id=info:doi/10.1007/s00345-015-1636-y&rft_dat=%3Cproquest_cross%3E3934996711%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1760724216&rft_id=info:pmid/26184106&rfr_iscdi=true |